Key result
Essential hypertension patients with the ACE DD genotype had significantly greater reduction in left ventricular mass index when treated with benazepril compared to II and ID genotypes (P<0.05).
Why the study?
Does the ACE gene I/D polymorphism or CMA gene A/B polymorphism affect the regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril?
Observational (n=157)
Does the ACE gene I/D polymorphism or CMA gene A/B polymorphism affect the regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril?
p-value: p=<0.05
Essential hypertension patients with the ACE DD genotype show greater regression of left ventricular hypertrophy when treated with benazepril compared to those with II or ID genotypes.
ACE DD genotype associated with greater benazepril-induced LVH regression; hypothesis-generating, requires validation before clinical use.
BACKGROUND: About 15-37% of the adult population worldwide suffers from hypertension. Hypertension is responsible for one-third of all global deaths. Left ventricular hypertrophy (LVH) is one of the most important characteristics of hypertension target organ damage and is also an independent risk factor for cardiovascular events. Therefore, effective regression of LVH is a main aim of hypertension treatment and also an important public health concern. However, few studies of the regression of LVH have been reported. In particular, little is known about the relationship between the genotypes of angiotensin-converting enzyme (ACE) and chymase (CMA) genes, and the effectiveness of antihypertensive drugs in regression of LVH. AIM: The study investigated whether the insertion/deletion (I/D) polymorphism of ACE gene and the A/B polymorphism of the CMA gene are related to the regression of LVH in essential hypertension patients who were participants in a long-term trial of therapy with benazepril. SUBJECTS AND METHODS: Data from 157 patients was collected and used in the analysis. The genotypes of ACE and CMA genes were identified by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Left ventricular mass (LVM) was measured by echocardiography, and left ventricular mass index (LVMI) was calculated. RESULTS: Blood pressure was markedly reduced and heart rate was unchanged by long-term treatment with benazepril. Regression of LVH was observed. The mean reduction in LVMI was 41.50+/-28.48 g m-2. Reduction of LVM, LVMI and percentage reduction of LVMI were more in the DD group than in the II and ID groups (P<0.05). No significant difference in other indices was found in the different genotype groups of ACE (P>0.05). No significant difference in all indices was found among the different genotype groups of CMA (P>0.05). No interaction was found between the genotypes of ACE and CMA. CONCLUSION: Hypertension patients with the DD genotype are more likely to have regression of LVH when treated with benazepril than patients with other genotypes of ACE. No evidence was found to support an association between CMA genotype and regression of LVH in patients or to support the interaction between the two genes in regression of LVH.
No takes yet. Share an insight, caveat, or question.
He et al. (2005) conducted an observational in Essential hypertension with left ventricular hypertrophy (n=157). Benazepril vs. ACE II and ID genotypes was evaluated on Reduction of left ventricular mass index (LVMI) (p=<0.05). Essential hypertension patients with the ACE DD genotype had significantly greater reduction in left ventricular mass index when treated with benazepril compared to II and ID genotypes (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: